Renascience Co., Ltd.
Tokyo, JP· latest recorded location
RENASCIENCE CO., LTD. is named on 8 US grants and 17 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 8
- Published applications
- 17
- Inventors
- 25
- Granted in 2026 so far
- 0
- Most recent grant
- 31 Jan 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 2 |
| 2012 | 0 | 2 |
| 2013 | 1 | 0 |
| 2014 | 2 | 2 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 3 |
| 2021 | 0 | 1 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
By publication year.
Technology areas
Share of 25 documents
- A61PTherapeutic uses of medicines22
- A61KMedicines and medical preparations15
- C07DHeterocyclic compounds9
- C07CAcyclic or carbocyclic compounds7
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms5
- G01NInvestigating or analysing materials by determining their chemical or physical properties5
- C12NMicroorganisms or enzymes3
- A23LFoods, foodstuffs or non-alcoholic beverages, not otherwise provided for2
- C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition2
- C07KPeptides1
Recent patents
- Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound31 Jan 2023US 11,564,924 B2
- Composition used to improve symptoms of autism spectrum disorder, and method using same for improving symptoms of autism spectrum disorder22 Feb 2022US 11,253,519 B2
- Use for PAI-1 inhibitor9 Oct 2018US 10,092,537 B2
- Detection and treatment of schizophrenia19 Aug 2014US 8,809,329 B2
- Plasminogen activator inhibitor-1 inhibitor22 Jul 2014US 8,785,473 B2
- Method for quantifying phenylalanine in blood, and measurement kit used therefor25 Jul 2024US 2024/0248095 A1
- Drug for enhancing fibrinolytic system, and use therefor9 Nov 2023US 2023/0355605 A1
- Inhibitor against expression of immune checkpoint molecule27 Oct 2022US 2022/0340665 A1
- Orally active small molecule inhibitor of pai-112 May 2022US 2022/0143185 A1
- Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound7 Jan 2021US 2021/0000829 A1
Most cited
By later US patents